Blockchain and Crypto Investing | The Problem with Passive Index Investing

 


In a world where digital currencies and blockchain technology are revolutionizing the financial landscape, the traditional approach of passive index investing is being critically examined. As the global market cap of cryptocurrencies surpassed $2 trillion in 2022, investors are compelled to reassess their strategies. The question arises: Is passive index investing still a viable option in the face of disruptive blockchain technology and crypto assets?

In the latest episode of Untamed Ethos, Dr. Joshua Wilson and Dr. Russell Rhoads engage with Dan Weiskopf to explore the impact of blockchain technology and crypto investing on traditional passive index investing, discussing the potential of blockchain in various industries and the role of Bitcoin futures in the institutionalization of cryptocurrency.

They discuss:

  • The distinction between investing in blockchain technology and investing in cryptocurrencies.
  • The potential of blockchain technology to revolutionize various industries, from finance to supply chain management.
  • The role of Bitcoin futures in the institutionalization of cryptocurrency.

About Joshua Wilson

Joshua Wilson is the founder of United Ethos Wealth Partners, a registered investment advisory firm. As a dedicated investment professional, he brings his wealth of knowledge and experience in finance to bear, guiding investors through the complexities of wealth management. Wilson is known for his authentic, unfiltered approach to discussing market trends and his commitment to providing meaningful insights to listeners.

About Dr. Russell Rhoads

Dr. Rhoads brings a wealth of knowledge from his extensive background in finance and business, currently serving as a Clinical Associate Professor at the Indiana University Kelley School of Business. His insights and understanding of market trends offer valuable perspectives on the current state of the stock market.

About Dan Weiskopf

Dan Weiskopf is a seasoned professional in the field of finance and investment. As the Lead ETF Strategist for Think Tank and Co-Portfolio Manager for Amplify Transformational Data Sharing ETF, he brings a wealth of knowledge and experience to the table. His insights into the evolving world of blockchain and crypto investing are sure to provide valuable perspectives for listeners.

Follow us on social media for the latest updates in B2B!

Image

Latest

What the Future Looks Like if We Get It Right
What the Future Looks Like if We Get It Right
December 30, 2025

As the Patient Monitoring series concludes, the conversation shifts from today’s challenges to tomorrow’s possibilities. This final episode of the five-part Health and Life Sciences at the Edge series looks ahead to what healthcare could become if patient monitoring gets it right. Intel’s Kaeli Tully is joined by Sudha Yellapantula, Senior Researcher at Medical…

Read More
data center infrastructure
AI Is Forcing a Rethink of Data Center Infrastructure at Every Level
December 29, 2025

The data center industry is being redefined by AI’s demand for faster, denser, and more scalable infrastructure. According to McKinsey, average rack power densities have more than doubled in just two years. It went from approximately 8 kW to 17 kW, and is expected to hit 30 kW by 2027. Global data center power demand is projected…

Read More
Emergency department
How Predictive AI Is Helping Hospitals Anticipate Admissions and Optimize Emergency Department Throughput
December 24, 2025

Emergency departments across the U.S. are under unprecedented strain, with overcrowding, staffing shortages, and inpatient bed constraints converging into a throughput crisis. The American Hospital Association reports that hospital capacity and workforce growth have lagged, intensifying delays from arrival to disposition. At the same time, advances in artificial intelligence are moving from experimental to operational—raising…

Read More
Mission
Why Is the Mission of Benchmark So Important
December 23, 2025

As pharmaceutical innovation accelerates, the margin for error narrows, making quality assurance not just a regulatory necessity but a public good. Benchmark’s mission sits at the intersection of progress and protection—helping manufacturers stay aligned with FDA standards so life-saving therapies reach patients faster and safer. By keeping cleanrooms compliant and companies out of trouble, Benchmark…

Read More